Role change
Tony J. Hunt
Executive Chair
RGEN ·
REPLIGEN CORP
Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors
Ready 8-Ks
22
Latest filing
May 15, 2026, 8:09 AM ET
Top materiality
0.80
Event mix
earnings ×10 · leadership ×5 · other_material ×3
Sentiment
8 pos · 3 neg · 11 neu
Latest earnings
reported 2026-Q1
Executive change
recent →
Recent 8-K filings for RGEN
Highest-materiality recent filing
Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M
- Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
- Q4 GAAP EPS $0.23 vs ($0.60); adjusted EPS $0.49 vs $0.44. Full year adjusted EPS $1.71 vs $1.58.
-
Repligen Q1 revenue $194M (+11% organic); raises adjusted EPS guidance to $1.97-$2.05
Q1 revenue $194M, +15% reported/+11% organic; GAAP EPS $0.15, adjusted EPS $0.48 (+23% YoY).
-
Repligen Q4 revenue $198M (+18%); FY26 guidance $810-840M
Q4 revenue $198M, up 18% reported and 14% organic YoY; full year 2025 revenue $738M (+16% reported and organic non-COVID).
-
Repligen Q3 revenue $189M (+22% YoY); raises FY2025 guidance to $729-737M
Revenue $189M, +22% reported, +18% organic; double-digit growth across all franchises.
-
Repligen Q2 revenue $182M (+17% organic non-COVID); orders >20% YoY; raises FY guidance
Revenue $182M, up 15% reported and 17% organic non-COVID YoY.
-
Repligen Q1 revenue $169M (+10% YoY); adjusted EPS $0.39 vs $0.30; orders up high-teens
Revenue $169M, up 10% reported, 14% organic non-COVID YoY; GAAP EPS $0.10, adjusted EPS $0.39.
-
Repligen Q4 revenue $168M; FY2024 $634M; guides FY2025 8-12% growth
Q4 revenue $168M, flat YoY; FY2024 revenue $634M vs $632M.
-
Repligen Q3 revenue $155M (+10% YoY); adjusted EPS $0.43 vs $0.23
GAAP net loss ($0.7M) vs income $17M; adjusted net income $24M vs $13M.
-
Restatement covers Q1'23 through Q2'24; $17.3M payment from cancelled COVID orders was mis-timed.
-
Repligen Q2 revenue $154M, adj. EPS $0.33, orders $157M; CEO transition, Tantti acquisition
Q2 2024 revenue $154M vs $159M prior year; GAAP EPS $0.06, adjusted EPS $0.33 vs $0.53.
-
Repligen appoints Olivier Loeillot as CEO effective Sept 1, 2024; Hunt becomes Executive Chair
Loeillot receives $750K base salary, 85% target bonus, and a $5M equity award (50% RSUs, 25% options, 25% PSUs).
-
Tony Hunt transitions from CEO to Executive Chair effective Sept 1, 2024; Olivier Loeillot named President and CEO.
-
Repligen Q1 revenue falls 17% to $151M; GAAP EPS $0.04, adjusted EPS $0.28
Q1 revenue $151.3M, down from $182.7M YoY; GAAP net income $2.1M ($0.04 diluted EPS) vs $28.8M ($0.51).
-
Repligen Q4 revenue down 16.6% to $155.7M; net loss $0.46/share
Q4 2023 revenue $155.7M vs $186.8M in Q4 2022; full year $638.8M vs $801.5M.
-
Repligen issues $600M of 1% convertible notes due 2028, exchanges $217.7M of 2024 notes
Issues $600M aggregate 1.00% Convertible Senior Notes due 2028; $309.9M exchanged for $217.7M of 0.375% notes due 2024, $290.1M for cash.
Executive changes
Appointed
Olivier Loeillot
President and Chief Executive Officer
RGEN ·
REPLIGEN CORP
Repligen has appointed Olivier Loeillot, Repligen’s President and Chief Commercial Officer, to the role of President and Chief Executive Officer, as successor to Tony J. Hunt, who will serve as Executive Chair of the Repligen board of directors (the “Board”), with such transition to be effective September 1, 2024
Role change
Karen A. Dawes
Lead Independent Director
RGEN ·
REPLIGEN CORP
appointed Karen A. Dawes, the Board’s current Chair, to the role of Lead Independent Director
Appointed
Olivier Loeillot
Member of the Board
RGEN ·
REPLIGEN CORP
the Board elected Mr. Loeillot as a member of the Board
Appointed
Margaret A. Pax
Director
RGEN ·
REPLIGEN CORP
the Board elected Margaret A. Pax to the Board, effective immediately (the “Effective Date”).
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.80 · Median 0.70 · Most common event earnings